Navigation Links
Premature ejaculation spray enables men to last 6 times longer after penetration
Date:4/6/2009

Men with premature ejaculation who used a topical spray five minutes before intercourse were able to delay their orgasm six times longer than normal, according to a study in the April issue of BJU International.

Three hundred men with clinically diagnosed lifelong premature ejaculation (PE) from 31 centres in the UK, Czech Republic, Hungary and Poland, were randomised into two groups. Two hundred used the PSD502 spray, which contains 7.5mg of lidocaine and 2.5mg of prilocaine, and 100 used a placebo spray with no active ingredients.

Every time they had intercourse during the three-month study period, each couple measured the time from vaginal penetration to ejaculation with a stopwatch. The men were asked to abstain from sexual activity or masturbation for 24 hours before each recorded encounter.

The time from penetration to ejaculation increased from an average of 0.6 minutes to 3.8 minutes in the medicated group and to just 1.1 minutes in the placebo group.

When these figures were adjusted to take account of any variations between the two groups, these showed that the treatment group were able to last 6.3 times longer after penetration when they used the spray. The placebo group lasted 1.7 times longer.

"Premature ejaculation can be a very distressing condition for men and can cause distress, frustration and make them avoid sexual intimacy" says lead researcher Professor W Wallace Dinsmore from the Royal Victoria Hospital, Belfast, UK.

The research team used the evidence-based definition of lifelong PE developed by the International Society for Sexual Medicine to select their study subjects. This states that ejaculation occurs within about one minute of vaginal penetration in the majority of encounters.

"Because this definition was only launched in 2008, studies have yet to determine the prevalence of lifelong PE in the male population" says Professor Dinsmore. "But previous research suggests that as many as 40% of men will experience premature ejaculation at some time in their lives."

The 300 men who took part in the phase three, multicentre, double-blind, randomised study had an average age of 35. The majority had used other treatments before, the most common being oral antidepressants.

After three months of treatment the researchers reported that:

  • 90% of the men in the treatment group were able to delay ejaculation for more than one minute following vaginal penetration, compared with 54% in the placebo group.

  • 74% of men in the treatment group managed to last more than two minutes before ejaculation, compared with 22% in the placebo group.

  • 62% of men in the treatment group said their orgasms were 'good' or 'very good' after three months, compared with 20% before the study started. The figures for the placebo group were slightly lower at the end (19%) than at the start (21%).

  • 66% of men in the treatment group said the medication was 'good' or 'excellent' compared with 15% in the placebo group.

  • A significantly higher percentage of the patients and partners in the treatment group reported improvements when it came to perceived control, personal distress, satisfaction with sexual intercourse and interpersonal difficulties.

  • There were no serious adverse events reported during the study. Adverse treatment-related reactions were reported by five men and six women from the treatment group and one man from the placebo group. The most common problems were loss of erection and a burning sensation in the vagina.

"Our study shows that when the PSD502 spray was applied to the man's penis five minutes before intercourse it improved both sexual performance and sexual satisfaction, which are key factors in treating premature ejaculation" says Professor Dinsmore.

"It was well tolerated by both patients and their partners, with no systemic side effects and a low incidence of localised effects and was rated favourably by the majority of users.

"We believe that this shows that PSD502 offers significant advantages over other therapies being developed for the treatment of premature ejaculation."


'/>"/>

Contact: Annette Whibley
wizard.media@virgin.net
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. New P.E. Drug Approved In Europe While Premature Ejaculation Cure Remains Out of Reach to American Men
2. Medical Costs for One Premature Baby Could Cover a Dozen Healthy Births
3. Medical costs for one premature baby could cover a dozen healthy births
4. Immune cells from patients with rheumatoid arthritis have prematurely aged chromosomes
5. UT Southwestern teaching hospital halves its rate of premature births, researchers find
6. Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden
7. New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls
8. DHA Hailed as Breakthrough Treatment for Lowering Risk of Developmental Disorders in Premature Infants; Animi-3(R) Prescribed to Women Who Are Not Eating Fish
9. La Rabida Children's Hospital's 13th Annual Symposium to Discuss Outcomes of Premature Birth
10. Premature babies have altered sensory responses in later life
11. Stanford/Packard study shows no benefit from drug widely used to prevent premature births
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts ... Secret. Dr. Wentz talked about journey and research recently on a blog and discussed ... the only solution to deal with thyroid disease. , Dr. Wentz completed her ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... advancing the science and clinical practice of radiosurgery, announced today the publication ... multi-institutional, observational registry established to standardize data collection from patients treated with ...
(Date:3/28/2017)... Wallingford, CT (PRWEB) , ... March 28, 2017 ... ... hemostatic devices, announces today that the University of Pittsburgh Medical Center (UPMC) will ... Central and Western Pennsylvania. , The program, developed in association with efforts by ...
(Date:3/28/2017)... , ... March 28, 2017 , ... The Radiology ... FRBMA, has begun to serve as its new executive director. Mr. Still was selected ... Search Committee. , “Bob, as he is known to our members, has been ...
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Research and Markets has announced the ... 2023" report to their offering. ... The ablation device global market is expected ... by 2023. Ablation is the minimally invasive therapeutic ... cancerous or diseased tissue removal, to the removal of abnormally conducting ...
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... March 29, 2017 On March 28, the U.S. Food ... patients with relapsing forms of multiple sclerosis (MS) and ... drug approved by the FDA for PPMS. Ocrevus is ... "Multiple sclerosis can have a profound ... , M.D., director of the Division of Neurology Products ...
Breaking Medicine Technology: